EW Edwards Lifesciences
- 87.420
- +2.330+2.74%
Edwards Lifesciences News
Edwards Lifesciences(EW.US) Officer Sells US$73,359.2 in Common Stock
$Edwards Lifesciences(EW.US)$ Officer Lippis Daniel J. sold 857 shares of common stock on May 7, 2024 at an average price of $85.6 for a total value of $73,359.2.Source: Announcement What is statement
The Zacks Analyst Blog Highlights Salesforce, BP, The Southern, PayPal and Edwards Lifesciences
Top Analyst Reports for Salesforce, BP & Southern Co.
Edwards Launches the SAPIEN 3 Ultra RESILIA Valve in Europe With Technology to Enhance Durability
NYON, Switzerland--(BUSINESS WIRE)-- Edwards Lifesciences today announced the European launch of the SAPIEN 3 Ultra RESILIA valve, the only transcatheter aortic heart valve to incorporate the company
Edwards Lifesciences(EW.US) Officer Buys US$49,752.72 in Common Stock
$Edwards Lifesciences(EW.US)$ Officer Zovighian Bernard J purchased 580.26 shares of common stock on May 6, 2024 at an average price of $85.7421 for a total value of $49,752.72.Source: Announcement Wh
Edwards Lifesciences Is Maintained at Overweight by Barclays
Edwards Lifesciences Is Maintained at Overweight by Barclays
Barclays: The Edwards Lifesciences (EW.US) rating was maintained, and the target price was adjusted from $100.00 to $101.00.
Barclays: The Edwards Lifesciences (EW.US) rating was maintained, and the target price was adjusted from $100.00 to $101.00.
Edwards Lifesciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 17.85% Barclays $100 → $101 Maintains Overweight 04/26/2024 15.52% Wells Fargo $94 → $99 Mainta
Barclays Adjusts Edwards Lifesciences Price Target to $101 From $100
Edwards Lifesciences (EW) has an average rating of outperform and price targets ranging from $73 to $105, according to analysts polled by Capital IQ. Price: 85.70, Change: +0.61, Percent Change: +0.72
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)
Investors Can Find Comfort In Edwards Lifesciences' (NYSE:EW) Earnings Quality
Shareholders appeared unconcerned with Edwards Lifesciences Corporation's (NYSE:EW) lackluster earnings report last week. Our analysis suggests that while the profits are soft, the foundations of the
Edwards Lifesciences(EW.US) Director Sells US$2.49 Million in Common Stock
$Edwards Lifesciences(EW.US)$ Director MUSSALLEM MICHAEL A sold 29,350 shares of common stock on May 2, 2024 at an average price of $84.77 for a total value of $2.49 million.Source: Announcement What
Edwards Lifesciences(EW.US) Officer Sells US$1.21 Million in Common Stock
$Edwards Lifesciences(EW.US)$ Officer Lemercier Jean-Luc M sold 14,400 shares of common stock on May 1, 2024 at an average price of $84.2144 for a total value of $1.21 million.Source: Announcement Wha
Edwards Lifesciences Insider Sold Shares Worth $1,212,687, According to a Recent SEC Filing
Jean-Luc M Lemercier, Corporate Vice President, EMEA, Canada, Latin America and Japan, Greater China and Asia Pacific, on May 01, 2024, sold 14,400 shares in Edwards Lifesciences (EW) for $1,212,687.
Jim Cramer: These Airline Stocks 'Trade Wildly,' Edwards Lifesciences 'At The Right Level To Buy'
On CNBC's "Mad Money Lightning Round," Jim Cramer said the new product line of Edwards Lifesciences Corporation (NYSE:EW) is "pulling back here." "That may be the right level to buy it. They are doing
Edwards Lifesciences(EW.US) Officer Sells US$622.06K in Common Stock
$Edwards Lifesciences(EW.US)$ Officer Ullem Scott B. sold 7,250 shares of common stock on Apr 30, 2024 at an average price of $85.8016 for a total value of $622.06K.Source: Announcement What is statem
Edwards Lifesciences Insider Sold Shares Worth $622,062, According to a Recent SEC Filing
Scott B. Ullem, Corporate Vice President, Chief Financial Officer, on April 30, 2024, sold 7,250 shares in Edwards Lifesciences (EW) for $622,062. Following the Form 4 filing with the SEC, Ullem has c
Edwards Lifesciences Corporation (NYSE:EW) Q1 2024 Earnings Call Transcript
Hold Rating Justified for Edwards Lifesciences Amid TAVR Segment Uncertainties
Maintaining Buy Rating on Edwards Lifesciences Amid Mixed TAVR Performance and Strong TMTT Growth
Analysis
Price Target
No Data
